| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/30/2009 | CA2703149A1 Idarubicin for the treatment of lymphoma in a dog |
| 04/30/2009 | CA2703138A1 Purine derivatives useful as pi3 kinase inhibitors |
| 04/30/2009 | CA2703054A1 Hydrated crystalline esters of camptothecin for the treatment of cancer |
| 04/30/2009 | CA2703044A1 Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy |
| 04/30/2009 | CA2702962A1 Combination therapy of a type ii anti-cd20 antibody with a proteasome inhibitor |
| 04/30/2009 | CA2702919A1 Use of lanthanide-based nanoparticles as radiosensitizing agents |
| 04/30/2009 | CA2702786A1 Novel imidazole derivatives |
| 04/30/2009 | CA2702502A1 Sdf-1-based glycosaminoglycan antagonists and methods of using same |
| 04/30/2009 | CA2701747A1 Novel imidazole derivatives |
| 04/30/2009 | CA2701276A1 Thienopyrimidiene derivatives as pi3k inhibitors |
| 04/30/2009 | CA2700210A1 Condensed compounds with activity at estrogen receptors |
| 04/30/2009 | CA2699805A1 Treatment regime for proliferative disorders |
| 04/30/2009 | CA2675342A1 A method for diagnosing disease using adenovirus harboring trans-splicing ribozyme by molecular imaging |
| 04/30/2009 | CA2609172A1 Immunotherapy compositions for use with targeted therapy in the treatment of cancer |
| 04/29/2009 | EP2053393A1 Pladienolide target molecule, compound capable of binding to the target molecule, and screening method for the compound |
| 04/29/2009 | EP2053129A2 Method of diagnosing, monitoring, staging, imaging and treating various cancers |
| 04/29/2009 | EP2053123A1 Method of proliferating lak cell |
| 04/29/2009 | EP2053061A1 Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor |
| 04/29/2009 | EP2053060A1 SDF-1-based glyocosaminoglycan antagonists and methods of using same |
| 04/29/2009 | EP2053039A1 Novel crystal of 5-aminolevulinic acid phosphate and process for production thereof |
| 04/29/2009 | EP2052742A1 Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination |
| 04/29/2009 | EP2052739A1 Cancer therapeutic agent comprising ligand for neuromedin u receptor 2 (fm4) molecule as active ingredient |
| 04/29/2009 | EP2052730A1 Composition for preventing and/or treating tumor containing component originating in the bark of tree belonging to the genus acacia |
| 04/29/2009 | EP2052725A2 Use of lanthanum compounds for the treatment of bone diseases |
| 04/29/2009 | EP2052723A1 Stable lyophilized preparation |
| 04/29/2009 | EP2052011A1 Targeted polylysine dendrimer therapeutic agent |
| 04/29/2009 | EP2051990A1 Smac peptidomimetics useful as iap inhibitors |
| 04/29/2009 | EP2051985A2 Pyrazolo[4,3-d]thiazole derivatives, and preparation and therapuetic application thereof |
| 04/29/2009 | EP2051982A1 6,6-bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors |
| 04/29/2009 | EP2051981A1 1h-furo[3,2-c] pyrazole compounds useful as kinase inhibitors |
| 04/29/2009 | EP2051980A1 Pyrrolotriazine kinase inhibitors |
| 04/29/2009 | EP2051974A1 Tetrahydrobenzothiophene derivatives |
| 04/29/2009 | EP2051969A1 Triazine derivative compound and composition for treating cancer containing them |
| 04/29/2009 | EP2051738A2 Drug delivery system based on regioselectively amidated hyaluronic acid |
| 04/29/2009 | EP2051718A2 Mesenchymal stem cells and uses therefor |
| 04/29/2009 | EP2051711A1 Thieno[3,2-c]pyridine-7-carboxylic acid derivatives |
| 04/29/2009 | EP1758935B1 High affinity telomerase t cell receptors |
| 04/29/2009 | EP1727555B1 Production of hop extracts having oestrogenic and antiproliferative bioactivity |
| 04/29/2009 | EP1720844B1 Pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl)-phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor xa in the treatment of thrombo-embolic diseases |
| 04/29/2009 | EP1687631B1 Methods for identifying compounds involved in the phosphoinositide-mediated signalling and use thereof in the manufacture of medicaments |
| 04/29/2009 | EP1542994B1 Novel oxazole compounds as transforming growth factor (tgf) inhibitor |
| 04/29/2009 | EP1485347B1 Hif hydroxylase inhibitors for use in the treatment of anaemia |
| 04/29/2009 | EP1454136B1 Methods and means for influencing intracellular communication and intracellular organelle transport |
| 04/29/2009 | EP1345910B1 Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof |
| 04/29/2009 | EP1265927B1 Crystal |
| 04/29/2009 | EP1257582B1 Method for inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity |
| 04/29/2009 | EP1218509B1 Fibroblast growth factor-like polypeptides |
| 04/29/2009 | EP1066286B1 Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
| 04/29/2009 | EP1047433A4 Cellulose derivatives and colorectal cancer risk reduction |
| 04/29/2009 | CN101421395A Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| 04/29/2009 | CN101421288A Novel amphiphilic derivatives of alpha-C-phenyl-N-tert-butylnitrone |
| 04/29/2009 | CN101421282A Treatment of hyperproliferative diseases with vinca alkaloidn-oxide and analogs |
| 04/29/2009 | CN101421276A Dimers of artemisinin derivatives, preparation thereof and therapeutic use thereof |
| 04/29/2009 | CN101421268A Pyrazoloquinolones as potent PARP inhibitors |
| 04/29/2009 | CN101421265A Thiazole compounds as protein kinase b (pkb) inhibitors |
| 04/29/2009 | CN101421260A Chromen-2-one derivatives |
| 04/29/2009 | CN101421253A Quinazolin-4-one derivatives, process for their preparation and pharmaceutical compositions containing them |
| 04/29/2009 | CN101421247A Novel imidazole derivatives, preparation and user thereof as medicine |
| 04/29/2009 | CN101421246A Layout of power semiconductor contacts on a cooling surface |
| 04/29/2009 | CN101420981A Combinations for the treatment of proliferative diseases |
| 04/29/2009 | CN101420978A Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
| 04/29/2009 | CN101420949A Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders |
| 04/29/2009 | CN101420945A Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| 04/29/2009 | CN101418325A Inonotus obliquus extracellular and incellular mixed exopolysaccharide and preparation method thereof and pharmaceutical use |
| 04/29/2009 | CN101418293A Tiny RNA-21 antisense oligonucleotides and use thereof |
| 04/29/2009 | CN101418270A High density culture method of lactobacillus casei Zhang, method for preparing freeze-dried powder by using the same and obtained freeze-dried powder and uses thereof |
| 04/29/2009 | CN101418039A Novel antibacterial peptide and preparation method and use thereof |
| 04/29/2009 | CN101418036A Rapid purification of gamma trichosanthin and crystallization technology thereof |
| 04/29/2009 | CN101417995A Phenoxy pyrimidine derivates and preparation method and use thereof |
| 04/29/2009 | CN101417974A Antitumor compound Cu(C10H12NO2)2 |
| 04/29/2009 | CN101417967A Histone deacetylase inhibitor, compounds thereof and use thereof |
| 04/29/2009 | CN101417949A Eicosatetraenoic acid derivates and preparation method and use thereof |
| 04/29/2009 | CN101417934A New compounds separated from Antrodia camphorate extract |
| 04/29/2009 | CN101417135A Preparation method of biodegradable fallout radioactive material for treating cancer |
| 04/29/2009 | CN101417134A Hyaluronic acid decorated novel tertiary structure non-virogene transmission system and use thereof |
| 04/29/2009 | CN101417129A Gabapentin analogues for fibromyalgia and other related disorders |
| 04/29/2009 | CN101417120A Methods for inducing sustained immune response |
| 04/29/2009 | CN101417101A Barbat skullcap gastric-cancer resistance granules and preparation method thereof |
| 04/29/2009 | CN101417078A Chinese herbal medicine preparation for treating leukaemia |
| 04/29/2009 | CN101417067A Medicine combination with anti-tumor function |
| 04/29/2009 | CN101417002A Red clover fresh grass pre-processing method |
| 04/29/2009 | CN101416988A New use of rosebay hornworm which eats madagascar periwinkle leaves and stool extract thereof in preparing anti-tumor medicine |
| 04/29/2009 | CN101416986A Arca extract enteric-coated capsules and manufacture method thereof |
| 04/29/2009 | CN101416985A Extraction method of arca extract freeze-drying powder |
| 04/29/2009 | CN101416979A Use of oligosaccharide in preparing medicine for treating tumor and inhibiting tumor metastasis |
| 04/29/2009 | CN101416962A Use of cytochalasin D in preparing anti-tumor medicine |
| 04/29/2009 | CN101416951A Preparation method of cmellia sponin controlled release tablets |
| 04/29/2009 | CN101416950A Preparation method of cmellia sponin controlled release tablets |
| 04/29/2009 | CN101416946A Biodegradable implantation controlled-release microsphere using vibration membrane technique |
| 04/29/2009 | CN101416941A Medical composition loaded with nimustine and synergist thereof |
| 04/29/2009 | CN101416938A Slow-released injection containing nolatrexed dihydrochloride and synergist thereof |
| 04/29/2009 | CN100482795C IREN protein, its preparation and use |
| 04/29/2009 | CN100482684C Cytokine protein family |
| 04/29/2009 | CN100482665C Pyrazolo 1,5-a pyrimidine derivatives |
| 04/29/2009 | CN100482664C 1,5-disubstituted-3,4-dihydro-1H-pyrimido [4,5-D] pyrimidi-2-one compounds and their use in treating CSBP/P38 kinase mediated diseases |
| 04/29/2009 | CN100482651C Diaminothiazoles |
| 04/29/2009 | CN100482285C Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ED-B |
| 04/29/2009 | CN100482284C Tracer or labelled isotope microbubble reagent with target substance and usage thereof |
| 04/29/2009 | CN100482283C Novel chimeric CD154 |
| 04/29/2009 | CN100482282C High water-soluble prodrug, and its preparing method and pharmaceutical use |